Positions

Selected Publications

Academic Article

Year Title Altmetric
2022 Challenges of Assessing Resident Competency in Well-Being: Development of the Psychiatry Milestones 2.0 Well-Being Subcompetency.  Academic Medicine.  97:351-356. 2022
2021 Psychiatry Milestones 2.0: Using the Supplemental Guide to Create a Shared Model of the Development of Professional Identity and Expertise.  Academic Psychiatry.  45:500-505. 2021
2021 Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset.  Journal of Clinical Psychiatry.  82. 2021
2021 Safety of Using a Combinatorial Pharmacogenomic Test for Patients with Major Depressive Disorder in the GUIDED trial 2021
2021 Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression.  Psychiatry Research.  296. 2021
2021 Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression.  Annals of Clinical Psychiatry.  33:18-26. 2021
2020 Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression.  American Journal of Geriatric Psychiatry.  28:933-945. 2020
2020 Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder.  Psychiatry Research.  290. 2020
2020 150 HAM-D6 Outcomes in a Randomized, Controlled Trial Evaluating the Utility of Combinatorial Pharmacogenomics in Depression 2020
2019 Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial.  BMC Psychiatry.  19. 2019
2019 Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care – The reality of treatment resistant-based therapies.  Journal of Psychiatric Research.  114:211-213. 2019
2019 Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study.  Journal of Psychiatric Research.  111:59-67. 2019
2019 Impact of pharmacogenomics on clinical outcomes for patients taking medications with gene-drug interactions in a randomized controlled trial.  Journal of Clinical Psychiatry.  80. 2019
2015 How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example..  The primary care companion for CNS disorders.  17. 2015
2014 Secondary psychosis 3 months prior to the overt symptoms of multiple myeloma: a case report..  The primary care companion for CNS disorders.  16. 2014
2012 How biomarkers will change psychiatry. Part II: Biomarker selection and potential inflammatory markers of depression..  Journal of Psychiatric Practice.  18:281-286. 2012
2012 How biomarkers will change psychiatry: from clinical trials to practice. Part I: introduction..  Journal of Psychiatric Practice.  18:118-121. 2012
2011 Phase I trials: from traditional to newer approaches part II..  Journal of Psychiatric Practice.  17:277-284. 2011
2011 Phase I trials: from traditional to newer approaches. Part I..  Journal of Psychiatric Practice.  17:200-203. 2011
2011 CYP 2D6 PM status and antidepressant response to nortriptyline and venlafaxine: is it more than just drug metabolism?.  Journal of Clinical Psychopharmacology.  31:143-145. 2011
2010 The Role of Benzodiazepines in the Treatment of Anxiety Disorders: A Clinical Review.  Psychiatric Annals.  40:605-610. 2010
2010 The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review..  Journal of Psychiatric Practice.  16:289-296. 2010
2010 Twenty percent of a representative sample of patients taking bupropion have abnormal, asymptomatic electroencephalographic findings..  Journal of Clinical Psychopharmacology.  30:312-317. 2010
2009 Duloxetine for the treatment of generalized anxiety disorder: a review..  Neuropsychiatric Disease and Treatment.  5:23-31. 2009
2008 A 19-year-old Black Woman with Psychotic and Depressive Symptoms.  Psychiatric Annals.  38. 2008
2000 Alaninyl­tryptophan hydrate, glycyl­tryptophan dihydrate and tryptophyl­glycine hydrate.  Acta Crystallographica Section C: Crystal Structure Communications.  56:e469-e471. 2000

Chapter

Year Title Altmetric
2012 Phase I Trials 2012

Principal Investigator On

Investigator On

Education And Training

  • Doctor of Osteopathy in Osteopathic Medicine / Osteopathy, University of Medicine and Denistry of New Jersey 2005
  • Bachelor of Arts in Chemistry, Rutgers University : Newark 2001

    • Full Name

  • Matthew Macaluso